<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815138</url>
  </required_header>
  <id_info>
    <org_study_id>13-098-3</org_study_id>
    <nct_id>NCT01815138</nct_id>
  </id_info>
  <brief_title>Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS</brief_title>
  <official_title>A Prospective Double-blind Randomized Trial Comparing Pregnancy Rates After Low Dose Human Chorionic Gonadotropin (hCG) at the Time of Gonadotropin Releasing Hormone (GnRH) Agonist Trigger or 35 Hours Later for the Prevention of OHSS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a prospective randomized double blind study involving patients at high risk of OHSS
      development with peak serum E2 levels &lt; 4,000 pg/ml comparing the ongoing pregnancy rates in
      patients who receive adjuvant hCG 1,000 IU at the time of GnRH agonist trigger or adjuvant
      hCG 1,500 IU 35 hours after GnRH agonist trigger.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of controlled ovarian
      hyperstimulation which may result in significant morbidity and rarely mortality as well as
      significant financial and psychological distress. GnRH agonist trigger has been shown to be
      effective in OHSS prevention. However, the adoption of its use has not been widely accepted
      in view of concerns regarding potential impairment of implantation.

      Intensive luteal phase supplementation with estrogen (E2) and progesterone (P) is important
      due to the strong evidence of abnormal luteal phase serum E2 and P profiles. However, it has
      been shown that optimal conception rates is not achieved for high risk patients with peak
      serum E2 &lt; 4,000 pg/ml despite aggressive steroidal supplementation. It has been proposed
      that the use of adjuvant low dose hCG at the time of GnRH agonist trigger or 35 hours later
      will rescue some of the corpora lutea and help improve corpora lutea function and improve
      pregnancy rates.

      The study will evaluate patients at high risk of OHSS development with peak serum E2 &lt; 4,000
      pg/mL to determine whether timing of low dose hCG administration affects ongoing pregnancy
      rates or risk of OHSS. Markers of corpus luteum function such as serum 17
      hydroxy-progesterone and prorenin during the luteal phase and early pregnancy will help
      elucidate further the effect of adjuvant low dose hCG with GnRH agonist trigger on corpus
      luteum function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing Pregnancy</measure>
    <time_frame>Through time of study completion, on average 1-2years</time_frame>
    <description>Positive serum pregnancy test and ultrasound evidence of fetal pole and fetal heart rate .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian Hyperstimulation Syndrome</measure>
    <time_frame>Within 4 weeks of oocyte retrieval</time_frame>
    <description>Evaluation of symptoms and signs of OHSS at 9 days after trigger of oocyte maturation. Patients who also present with symptoms of OHSS wil also be evaluated for OHSS within 4 weeks after oocyte maturation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Markers of Corpus Luteum Function</measure>
    <time_frame>Within 60 days after trigger of oocyte maturation</time_frame>
    <description>A subset of patients (20 patients in each group) will have serum frozen for subsequent analysis of 17 hydroxy progesterone and prorenin.</description>
  </other_outcome>
  <other_outcome>
    <measure>Abdominal Distension</measure>
    <time_frame>Within 2 weeks after trigger of oocyte maturation</time_frame>
    <description>Patients will complete a questionnaire to determine if there is a difference in the effect of the intervention on the quality of life (abdominal distension) of the patients from the day of trigger of oocyte maturation until menses or positive pregnancy test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>hCG given at time of GnRHa trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG given 35 hours after GnRHa trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
    <arm_group_label>hCG given at time of GnRHa trigger</arm_group_label>
    <other_name>Pregnyl, Profasi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
    <arm_group_label>hCG given 35 hours after GnRHa trigger</arm_group_label>
    <other_name>Pregnyl, Profasi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal baseline serum follicle stimulating hormone, polycystic ovarian syndrome
             (PCOS), Polycystic ovarian morphology, Previous high responder or previous OHSS, must
             have &gt; 14 follicles of over 11 mm in diameter and with peak serum E2 levels &lt; 4,000
             pg/mL on the day of trigger of oocyte maturation.

        Exclusion Criteria:

          -  Hypothalamic dysfunction, Patients with &lt; 14 follicles &lt; 11 mm in diameter, peak serum
             E2 levels &gt;= 4,000 pg/mL.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Engmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril. 2012 Jun;97(6):1316-20. doi: 10.1016/j.fertnstert.2012.03.015. Epub 2012 Apr 3.</citation>
    <PMID>22480822</PMID>
  </reference>
  <reference>
    <citation>Kummer N, Benadiva C, Feinn R, Mann J, Nulsen J, Engmann L. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. Fertil Steril. 2011 Jul;96(1):63-8. doi: 10.1016/j.fertnstert.2011.04.050. Epub 2011 May 12.</citation>
    <PMID>21565337</PMID>
  </reference>
  <reference>
    <citation>Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008 Jan;89(1):84-91. Epub 2007 Apr 26.</citation>
    <PMID>17462639</PMID>
  </reference>
  <reference>
    <citation>Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online. 2009 May;18(5):630-4.</citation>
    <PMID>19549440</PMID>
  </reference>
  <reference>
    <citation>Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online. 2006 Aug;13(2):173-8.</citation>
    <PMID>16895629</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2013</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>August 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2017</results_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Lawrence Engmann</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>OHSS, GnRH agonist trigger, low dose hCG, PCOS, IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All patients that met initial study criteria were enrolled and consented before starting ovarian stimulation. Final randomization occurred during stimulation. Therefore patients who were enrolled and consented may drop out before randomization, either because they did not meet the final inclusion criteria in did not undergo IVF.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>hCG Given at Time of GnRHa Trigger</title>
          <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger
hCG: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
        </group>
        <group group_id="P2">
          <title>hCG Given 35 Hours After GnRHa Trigger</title>
          <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.
hCG: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>hCG Given at Time of GnRHa Trigger</title>
          <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger
hCG: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
        </group>
        <group group_id="B2">
          <title>hCG Given 35 Hours After GnRHa Trigger</title>
          <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.
hCG: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="3.3"/>
                    <measurement group_id="B2" value="32.2" spread="3.4"/>
                    <measurement group_id="B3" value="31.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>&quot;kg/m^2&quot;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="4.8"/>
                    <measurement group_id="B2" value="27.4" spread="5.5"/>
                    <measurement group_id="B3" value="26.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti Mullerian Hormone (AMH)</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="5.8"/>
                    <measurement group_id="B2" value="8.4" spread="4.9"/>
                    <measurement group_id="B3" value="8.35" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follicle Stimulating Hormone (FSH)</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="1.7"/>
                    <measurement group_id="B2" value="5.2" spread="1.6"/>
                    <measurement group_id="B3" value="5.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ongoing Pregnancy</title>
        <description>Positive serum pregnancy test and ultrasound evidence of fetal pole and fetal heart rate .</description>
        <time_frame>Through time of study completion, on average 1-2years</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>hCG Given at Time of GnRHa Trigger</title>
            <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger
hCG: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
          </group>
          <group group_id="O2">
            <title>hCG Given 35 Hours After GnRHa Trigger</title>
            <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.
hCG: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
          </group>
        </group_list>
        <measure>
          <title>Ongoing Pregnancy</title>
          <description>Positive serum pregnancy test and ultrasound evidence of fetal pole and fetal heart rate .</description>
          <population>per protocol analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ovarian Hyperstimulation Syndrome</title>
        <description>Evaluation of symptoms and signs of OHSS at 9 days after trigger of oocyte maturation. Patients who also present with symptoms of OHSS wil also be evaluated for OHSS within 4 weeks after oocyte maturation.</description>
        <time_frame>Within 4 weeks of oocyte retrieval</time_frame>
        <population>Women with normal or high response to IVF, peak estradiol on day of trigger less than 4000 pg/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>hCG Given at Time of GnRHa Trigger</title>
            <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger
hCG: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
          </group>
          <group group_id="O2">
            <title>hCG Given 35 Hours After GnRHa Trigger</title>
            <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.
hCG: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
          </group>
        </group_list>
        <measure>
          <title>Ovarian Hyperstimulation Syndrome</title>
          <description>Evaluation of symptoms and signs of OHSS at 9 days after trigger of oocyte maturation. Patients who also present with symptoms of OHSS wil also be evaluated for OHSS within 4 weeks after oocyte maturation.</description>
          <population>Women with normal or high response to IVF, peak estradiol on day of trigger less than 4000 pg/mL.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Markers of Corpus Luteum Function</title>
        <description>A subset of patients (20 patients in each group) will have serum frozen for subsequent analysis of 17 hydroxy progesterone and prorenin.</description>
        <time_frame>Within 60 days after trigger of oocyte maturation</time_frame>
        <population>Subset of women included in larger study, normal or high responders, peak estradiol level less than 4000 pg/mL on day of trigger.</population>
        <group_list>
          <group group_id="O1">
            <title>hCG Given at Time of GnRHa Trigger</title>
            <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger
hCG: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
          </group>
          <group group_id="O2">
            <title>hCG Given 35 Hours After GnRHa Trigger</title>
            <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.
hCG: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Corpus Luteum Function</title>
          <description>A subset of patients (20 patients in each group) will have serum frozen for subsequent analysis of 17 hydroxy progesterone and prorenin.</description>
          <population>Subset of women included in larger study, normal or high responders, peak estradiol level less than 4000 pg/mL on day of trigger.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Early luteal 17-OH-Progesterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.68" spread="11.0"/>
                    <measurement group_id="O2" value="21.77" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16 Prorenin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.8"/>
                    <measurement group_id="O2" value="2.22" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Abdominal Distension</title>
        <description>Patients will complete a questionnaire to determine if there is a difference in the effect of the intervention on the quality of life (abdominal distension) of the patients from the day of trigger of oocyte maturation until menses or positive pregnancy test.</description>
        <time_frame>Within 2 weeks after trigger of oocyte maturation</time_frame>
        <population>Some patients did not complete the questionnaire. Abdominal distension analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>hCG Given at Time of GnRHa Trigger</title>
            <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger
hCG: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
          </group>
          <group group_id="O2">
            <title>hCG Given 35 Hours After GnRHa Trigger</title>
            <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.
hCG: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
          </group>
        </group_list>
        <measure>
          <title>Abdominal Distension</title>
          <description>Patients will complete a questionnaire to determine if there is a difference in the effect of the intervention on the quality of life (abdominal distension) of the patients from the day of trigger of oocyte maturation until menses or positive pregnancy test.</description>
          <population>Some patients did not complete the questionnaire. Abdominal distension analyzed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal distension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>hCG Given at Time of GnRHa Trigger</title>
          <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger
hCG: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
        </group>
        <group group_id="E2">
          <title>hCG Given 35 Hours After GnRHa Trigger</title>
          <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.
hCG: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <description>Patient diagnosed with un-ruptured ectopic pregnancy and required a laparoscopy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lawrence Engmann</name_or_title>
      <organization>UConn Helth</organization>
      <phone>8605258283</phone>
      <email>lengmann@uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

